Therapeutic Strategies for Ovarian Cancer in Point of HGF/c-MET Targeting

被引：6
作者：
Kim, Hyun Jung [1 ,2 ,3 ]
机构：
[1] Kookmin Univ, Dept Biopharmaceut Chem, Seoul 02707, South Korea
[2] Kookmin Univ, Sch Appl Chem, Seoul 02707, South Korea
[3] Kookmin Univ, Antibody Res Inst, Seoul 02707, South Korea
来源：
MEDICINA-LITHUANIA | 2022年 / 58卷 / 05期
基金：
新加坡国家研究基金会;
关键词：
hepatocyte growth factor; c-MET; ovarian cancer; humanized monoclonal antibody; anti-cancer; therapeutics; HEPATOCYTE GROWTH-FACTOR; RECURRENT EPITHELIAL OVARIAN; RECEPTOR TYROSINE KINASE; PHASE-II EVALUATION; C-MET; SCATTER FACTOR; FALLOPIAN-TUBE; MESENCHYMAL TRANSITION; FACTOR/SCATTER FACTOR; CLINICAL-SIGNIFICANCE;
D O I：
10.3390/medicina58050649
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Ovarian cancer is the fifth leading cause of cancer deaths in women and is regarded as one of the most difficult cancers to treat. Currently, studies are being conducted to develop therapeutic agents for effective treatment of ovarian cancer. In this review, we explain the properties of the hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (c-MET) and how the signaling pathway of HGF/c-MET is activated in different cancers and involved in tumorigenesis and metastasis of ovarian cancer. We present the findings of clinical studies using small chemicals or antibodies targeting HGF/c-MET signaling in various cancer types, particularly in ovarian cancer. We also discuss that HGF/c-MET-targeted therapy, when combined with chemo drugs, could be an effective strategy for ovarian cancer therapeutics.
引用
收藏
页数：12
相关论文
共 108 条
[81]   The prognostic value of dividing epithelial ovarian cancer into type I and type II tumors based on pathologic characteristics [J].
Prahm, Kira Philipsen ;
Karlsen, Mona Aarenstrup ;
Hogdall, Estrid ;
Scheller, Nikolai Madrid ;
Lundvall, Lene ;
Nedergaard, Lotte ;
Christensen, Ib Jarle ;
Hogdall, Claus .
GYNECOLOGIC ONCOLOGY, 2015, 136 (02) :205-211
[82]   Optimal first-line treatment in ovarian cancer [J].
Raja, F. A. ;
Chopra, N. ;
Ledermann, J. A. .
ANNALS OF ONCOLOGY, 2012, 23 :118-127
[83]   Clinical use of crizotinib for the treatment of non-small cell lung cancer [J].
Roberts, Patrick J. .
BIOLOGICS-TARGETS & THERAPY, 2013, 7 :91-101
[84]   ALTERNATIVE SPLICING GENERATES ISOFORMS OF THE MET RECEPTOR TYROSINE KINASE WHICH UNDERGO DIFFERENTIAL PROCESSING [J].
RODRIGUES, GA ;
NAUJOKAS, MA ;
PARK, M .
MOLECULAR AND CELLULAR BIOLOGY, 1991, 11 (06) :2962-2970
[85]   Managing treatment-related adverse events associated with Alk inhibitors [J].
Rothenstein, J. M. ;
Letarte, N. .
CURRENT ONCOLOGY, 2014, 21 (01) :19-26
[86]   Essential role of Gab1 for signaling by the c-Met receptor in vivo [J].
Sachs, M ;
Brohmann, H ;
Zechner, D ;
Müller, T ;
Hülsken, J ;
Walther, I ;
Schaeper, U ;
Birchmeier, C ;
Birchmeier, W .
JOURNAL OF CELL BIOLOGY, 2000, 150 (06) :1375-1384
[87]  
Sahu Arvind, 2013, South Asian J Cancer, V2, P91, DOI 10.4103/2278-330X.110506
[88]   c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion [J].
Sawada, Kenjiro ;
Radjabi, A. Reza ;
Shinomiya, Nariyoshi ;
Kistner, Emily ;
Kenny, Hilary ;
Becker, Amy R. ;
Turkyilmaz, Muge A. ;
Salgia, Ravi ;
Yamada, S. Diane ;
Vande Woude, George F. ;
Tretiakova, Maria S. ;
Lengyel, Ernst .
CANCER RESEARCH, 2007, 67 (04) :1670-1679
[89]   Natural history and outcome of mucinous carcinoma of the ovary [J].
Schiavone, Maria B. ;
Herzog, Thomas J. ;
Lewin, Sharyn N. ;
Deutsch, Israel ;
Sun, Xuming ;
Burke, William M. ;
Wright, Jason D. .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2011, 205 (05) :480.e1-480.e8
[90]   Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma [J].
Seidel, C ;
Borset, M ;
Turesson, I ;
Abildgaard, N ;
Sundan, A ;
Waage, A .
BLOOD, 1998, 91 (03) :806-812
234567891011